Janus Kinase (JAK) Inhibitors For Rheumatoid Arthritis (RA) In Paediatric
Background: Janus kinase inhibitors (JAKi) are a novel family of oral targeted disease-modifying medications that have lately changed the treatment of immune-mediated disorders including rheumatoid arthritis (RA) and others by coexisting with or even replacing traditional and biological medications. The most prevalent paediatric rheumatic illness and a major contributor to developmental impairment is juvenile idiopathic arthritis (JIA).
Objective: The aim of this review was to highlight and characterize Janus kinase inhibitors for use in paediatric rheumatology patients.
Methods: The following keywords were used in searches of PubMed, Google Scholar, and Science Direct: Janus kinase, JAK therapy, and Pediatric rheumatoid arthritis. Only the most current or comprehensive study was included after the authors thoroughly filtered references from the pertinent literature, including all the recognised studies and reviews.
Conclusion: Although none of the currently available medications have the ability to cure an illness, prognosis has significantly improved as a consequence of significant advancements in disease treatment. The emergence of biologic therapies, which provide paediatric patients who are resistant to traditional antirheumatic drugs a viable therapy alternative, has been the most significant recent breakthrough.
Oral JAKinib treatments signal the beginning of a potentially interesting period in paediatric rheumatology; their significance in JIA is particularly expected for wider clinical practise, while their potential benefits for uncommon disorders are also presumed.